IGC Pharma, Inc. (IGC) stock
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3021% above fair value
$0.18−0.01 (-7.24%)
Close on Nov 12, 2026Market cap $19.07MP/E –Yield –
IGC Pharma EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
IGC Pharma's EPS for the twelve months ending Jun 30, 2026 was -$0.08. For fiscal 2025 it was -$0.09. The highest annual figure on record is -$0.06 in fiscal 2018.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | -$0.09 | – |
| FY2024 | Mar 31, 2024 | -$0.22 | – |
| FY2021 | Mar 31, 2021 | -$0.21 | – |
| FY2020 | Mar 31, 2020 | -$0.19 | – |
| FY2019 | Mar 31, 2019 | -$0.13 | – |
| FY2018 | Mar 31, 2018 | -$0.06 | – |
| FY2017 | Mar 31, 2017 | -$74.34 | – |
| FY2016 | Mar 31, 2016 | -$180.54 | – |
| FY2015 | Mar 31, 2015 | -$329.22 | – |
| FY2014 | Mar 31, 2014 | -$392.94 | – |
| FY2013 | Mar 31, 2013 | -$339.84 | – |
| FY2012 | Mar 31, 2012 | -$2824.92 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$0.03 | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$0.02 | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$0.01 | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$0.02 | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$0.02 | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$0.02 | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$0.02 | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$0.02 | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$0.03 | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$0.04 | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$0.09 | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$0.05 | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$0.04 | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$0.08 | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$0.04 | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$0.05 | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$0.05 | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$0.13 | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$0.05 | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$0.09 | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$0.04 | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$0.07 | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$0.06 | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$0.04 | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$0.05 | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$0.08 | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$0.04 | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$0.03 | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$0.03 | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$0.03 | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$0.03 | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$0.02 | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$0.02 | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$0.01 | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$21.24 | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -$39.64 | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $0.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?